Contact us Find a person

Hepatitis C modelling

Our modelling aims to help countries identify the most effective and cost-effective ways to eliminate hepatitis C as a public health threat.

We are aiming to answer the following questions in a range of settings:

How much will prevention, testing and treatment need to be scaled up among different population groups to achieve elimination targets?
What are the most cost-effective delivery modalities for different interventions, among different population groups?
What is the minimal cost to reach strategic targets, and the expected return-on-investment?
How can budgets be optimised to achieve the greatest impact?

Reports

Eliminating hepatitis C in Myanmar

Burnet Institute’s Eliminate Hepatitis C program is playing a leading role working with the Myanmar Ministry of Health and Sports, Myanmar Liver Foundation, Clinton Health Access Initiative and other key stakeholders to expand hepatitis C care in Myanmar.
Eliminating Hepatitis C in Myanmar [PDF 1.1 MB]

Featured publications

Reaching hepatitis C virus elimination targets requires health system interventions to enhance the care cascade

International Journal of Drug Policy

Jess Howell, Nick Scott, Joseph Doyle, David P. Wilson, Amanda Wade, Alisa Pedrana, Margaret Hellard, Nick Scott, Joseph Doyle, David P. Wilson

Treatment scale-up to achieve global HCV incidence and mortality elimination targets: a cost-effectiveness model

Gut

Nick Scott, Emma S. McBryde, Joseph Doyle, Margaret Hellard, Nick Scott, Emma S. McBryde, Joseph Doyle, Margaret Hellard

Limited provision of diagnostic services to Victorians living with hepatitis C antibodies, 2001–2012: a multi‐level modelling analysis

Australian and New Zealand Journal of Public Health

Nick Scott

The Potential Impact of a Hepatitis C Vaccine for People Who Inject Drugs: Is a Vaccine Needed in the Age of Direct-Acting Antivirals?

PLoS ONE

Margaret Hellard, Nick Scott, Emma S. McBryde, Heidi E. Drummer

Modelling hepatitis C transmission over a social network of injecting drug users

Journal of Theoretical Biology

Rachel Sacks‐Davis, Margaret Hellard, Rebecca Jenkinson

The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments

BMC Medicine

Nick Scott, Emma S. McBryde, Heidi E. Drummer, Margaret Hellard

Partners

Funding partners

National Health and Medical Research Council, Australia

Project contacts

Main contact

Associate Professor Nick Scott

Associate Professor Nick Scott

Head, Modelling and Biostatistics

nick.scott@burnet.edu.au +61385062410

Project team

Associate Professor Nick Scott

Associate Professor Nick Scott

Head, Modelling and Biostatistics

Dr Rachel Sacks-Davis

Dr Rachel Sacks-Davis

Senior Research Fellow

Dr Farah Houdroge

Dr Farah Houdroge

Research Officer

Phillip Luong

Phillip Luong

Mathematical Modeller

Anna Palmer

Anna Palmer

Honorary Associate

Professor Margaret Hellard AM

Professor Margaret Hellard AM

Deputy Director, Programs; Adjunct Professor, Monash University, DEPM.

On this page